Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity, June 25-26, 2018 in Bethesda, MD


Overview

Cancer treatment-related cardiotoxicity is a leading cause of treatment-associated morbidity and mortality in cancer survivors. The gaps in knowledge related to cardiotoxicity are large, including mechanisms of cardiac injury, clinical prediction, screening, prevention, and treatment, as well as the similarities and differences between cancer induced cardiotoxicity and primary cardiovascular disease.

This conference was sponsored by the National Cancer Institute (NCI) and the National Heart, Lung, and Blood Institute (NHLBI). Its goal was to bring together experts in multiple disciplines within cardiology and oncology to discuss progress over the past five years and redefine research priorities moving forward.

Return to Top

Agenda


View agenda for Monday, June 25

NIH Natcher Conference Center (Building 45), Balcony A & B
45 Center Drive, Bethesda, MD 20894

Time Topic
8:00 a.m. - 8:30 a.m. Registration
Session 1: Cancer Treatment-Related Cardiotoxicity: 5 Years of Progress
Moderator: Bishow Adhikari
8:30 a.m. - 9:10 a.m.

NCI/NHLBI 2013 Cardiotoxicity Workshop and FOA: Where are we now?
Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N.
NCI Division of Cancer Control and Population Sciences

NIH Cardiotoxicity Task Force
Eileen Dimond, R.N., M.S.
NCI Division of Cancer Prevention

NCORP Trials: Evolving Cardio-Oncology Study Designs
Lori Minasian, M.D.
NCI Division of Cancer Prevention

Heart Failure Network: Collaborations in Cancer Cardiotoxicity Patrice Desvigne-Nickens, M.D.
NHLBI Division of Cardiovascular Sciences

Session 2: Translating Cardio-Oncology Findings
Moderator: Javid Moslehi, M.D.
Vanderbilt University
9:10 a.m. - 9:25 a.m.

Non-clinical Toxicology: Moving Forward
Myrtle Davis-Millin, Ph.D.
Bristol Meyers Squibb

9:25 a.m. - 9:40 a.m.

Vascular Cardio-Oncology: Mechanisms and Implications Moving Forward
Javid Moslehi, M.D.
Vanderbilt University

9:40 a.m. - 10:00 a.m.

Moving Novel Cardiotoxicity Assays into Trials
Joseph Wu, M.D., Ph.D.
Stanford University

10:00 a.m. - 10:20 a.m.

Translating Pediatric Cardiotoxicity Research to Other Populations
Steven Lipshultz, M.D.
Wayne State University

10:20 a.m. - 10:40 a.m. Break
10:40 a.m. - 11:10 a.m.

Prevention Exemplar: Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors
Saro Armenian, M.D.
City of Hope

11:10 a.m. - 11:40 a.m.

Translation Exemplar: Energy Balance in Cardiotoxicity: Moving Mechanisms to Clinical Studies
Eugenie Kleinerman, M.D.
MD Anderson Cancer Center

11:40 a.m. - 12:20 p.m.

Discussion and Audience Response
Discussants:

Javid Moslehi, M.D.
Vanderbilt University

Eric Chow, M.D.
Fred Hutchinson Cancer Center

  • What are the catalysts and barriers to moving mechanisms into pre-clinical models and clinical interventions?
  • What mechanistic and pre-clinical findings are ready to move into clinical studies?
  • FOA: What are the most promising translational models to test the efficacy of potential cardio-protective agents and other drug combinations proposed to optimize cancer treatment and mitigate cardiovascular damage?
12:20 p.m. - 1:20 p.m. Lunch (cafeteria on site)
1:20 p.m. - 1:50 p.m.

Key Note: Immunotherapy and Cardiotoxicity: Staying Ahead of the Curve
Javid Moslehi, M.D.
Vanderbilt University

Session 3: Assessing Pre-Treatment Risk to Improve Cardiotoxicity Outcomes
Moderator: Susan Dent, M.D.
The Ottawa Hospital Cancer Centre
1:50 p.m. - 2:00 p.m.

Building the Evidence Base: Guideline Gaps in Risk Assessment
Saro Armenian, M.D.
City of Hope

2:00 p.m. - 2:15 p.m.

Standardizing the Collection of Cardiovascular Risk Factors: ECOG-ACRIN Case Report Form
Bonnie Ky, M.D.
University of Pennsylvania

2:15 p.m. - 2:30 p.m.

Pharmacogenomic Testing to Predict Cardiotoxicity and Inform Cancer Treatment Decisions
Colin Ross, Ph.D.
BC Children’s Hospital

2:30 p.m. - 2:45 p.m.

Predictors of Cardiovascular Disease among Breast Cancer Survivors in an Integrated Health System
Marilyn Kwan, Ph.D.
Kaiser Permanente Northern California

2:45 p.m. - 3:00 p.m.

Dietary Fats, Mitochondrial Function and Muscle Health: Predicting Risk
Martha Belury, Ph.D., R.D.
Ohio State University

3:00 p.m. - 3:40 p.m.

Discussion and Audience Response
Discussant:

Joanna Brell, M.D.
MetroHealth Medical Center

Laleh Amiri Kordestani, M.D.
Food and Drug Administration

  • What are the catalysts and barriers to integrating risk tools into clinical practice?
  • What clinical risk findings are ready to move into validation studies and/or guidelines?
  • FOA: What are the best translational models to test the efficacy of potential cardio-protective agents and other drug combinations proposed to optimize cancer treatment and mitigate cardiovascular damage?
3:40 p.m. - 4:00 p.m. Break
Session 4: Cardiotoxicity Detection - Biomarkers and Imaging
Moderator: Ana Barac, M.D.
Washington Hospital Center
4:00 p.m. - 4:10 p.m.

Building the Evidence Base: Guideline Gaps in Detection
Saro Armenian, M.D.
City of Hope

4:10 p.m. - 4:25 p.m.

Standardizing Biomarker and Imaging Across Studies: ECHO Exemplar
Bonnie Ky, M.D.
University of Pennsylvania

4:25 p.m. - 4:40 p.m.

Cardiac Assay Utilization Post Cancer Treatment: BEAT HF
Joerg Hermann, M.D.
Mayo Clinic

4:40 p.m. - 4:55 p.m.

Surveillance: Who, When and How?
Chau Dang, M.D.
Memorial Sloan Kettering Cancer Center

4:55 p.m. - 5:30 p.m.

Discussion and Audience Response
Discussant:

Anthony Yu, M.D.
Memorial Sloan Kettering Cancer Center

  • What are the catalysts and barriers to integrating detection/screening techniques into clinical practice?
  • What detection/screening findings are ready to move into validation studies and/or guidelines?
  • FOA: How can we utilize known and novel genetic markers, pharmacogenomic measures, biomarkers, imaging tools and other measures, including combinations of measures, to identify sub-clinical derangements, define cardio-oncology risk, monitor cardiovascular function and guide effective and safe management strategies?
  • FOA: How does early detection and management of cardiotoxicity impact cardiac and cancer short- and long-term outcomes?
5:30 p.m. Adjourn

View agenda for Tuesday, June 26

NIH Natcher Conference Center (Building 45), Balcony A & B
45 Center Drive, Bethesda, MD 20894

Time Topic
8:00 a.m. - 8:30 a.m. Registration
8:30 a.m. - 8:40 a.m.

Welcome
Bishow Adhikari, Ph.D.
NHLBI, Division of Cardiovascular Sciences

8:40 a.m. - 9:10 a.m.

Key Note: The Intersection of Spaceflight and Cancer Cardiotoxicity: Exercise Training-Induced Cardioprotection
Jessica Scott, Ph.D.
Memorial Sloan Kettering Cancer Center

Session 5: Cardiotoxicity Prevention and Management Strategies
Moderator: Greg Hundley, M.D.
Wake Forest Baptist Hospital
9:10 a.m. - 9:20 a.m.

Building the Evidence Base: Guideline Gaps in Prevention and Management
Saro Armenian, M.D.
City of Hope

9:20 a.m. - 9:35 a.m.

Photon versus Proton Radiation and Cardiac Outcomes
Justin Bekelman, M.D.
University of Pennsylvania

9:35 a.m. - 9:50 a.m.

Dual Action RSK Inhibitor: Targeting Metastasis and Providing Cardioprotection
Deborah Lannigan, Ph.D.
Vanderbilt University Medical Center

9:50 a.m. - 10:05 a.m.

Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy
Eric Chow, M.D.
Fred Hutchinson Cancer Center

10:05 a.m. - 10:20 a.m.

WISER Survivorship: Management of Weight and Exercise
Kathryn Schmitz, Ph.D., M.P.H.
University of Pennsylvania

10:20 a.m. - 10:40 a.m. Break
10:40 a.m. - 10:55 a.m.

Exercise Interventions in Cancer Survivors
Chunkit Fung, M.D.
University of Rochester

10:55 a.m. - 11:10 a.m.

Integrating Cardio-oncology into Cancer Survivorship Care
Jennifer Klemp, Ph.D.
University of Kansas

11:10 a.m. - 11:50 a.m.

Discussion and Audience Response
Discussant:

Greg Hundley, M.D.
Wake Forest Baptist Health

  • What are the catalysts and barriers to integrating detection/screening techniques into clinical practice?
  • What detection/screening findings are ready to move into validation studies and/or guidelines?
  • FOA: How can we utilize therapeutic and behavioral interventions that do not interfere with anti-cancer therapy efficacy but can mitigate or reverse cardiovascular damage?
  • FOA: What are the optimal pharmacologic and non-pharmacologic approaches to prevent cancer treatment-related cardiotoxicity during cancer treatment and survivorship care, and what risk assessment strategies can best identify higher risk patient subgroups that are most likely to receive the greatest benefit from these approaches?
Session 6: Setting Short- and Long-term Goals
Moderators: NCI/NHLBI Cardiotoxicity Team
11:50 a.m. - 12:30 p.m.

Setting Priorities - A 10-Year Plan (Open Discussion)

  • Leveraging existing resources
  • Establishing new resources
  • Knowledge Gaps
  • What have we learned from cardiotoxicity research in breast cancer and pediatrics that is ready for validation in other understudied populations (disease, treatment, age, race)?
  • How to overcome barriers to studying cardiac outcomes among understudying cancer populations and new cancer treatments?
12:30 p.m. Adjourn

Return to Top

Steering Committee

Return to Top

Contact

For further information or questions, contact Nonniekaye Shelburne, C.R.N.P., M.S., A.O.C.N., Program Director, Clinical and Translational Epidemiology Branch, Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, NCI.

Return to Top